Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX·AMEX

$3.33

-7.5%
HealthcareMedical - Devices

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

At a Glance

Live Snapshot
Market Cap$257.24M
EPS-1.4000
P/E Ratio-2.38
Earnings Date08/12/2026

catx

Other Non-Current Assets

Last Annual Value

486.00K

3-Year CAGR

30%

5-Year CAGR

5%

10-Year CAGR

-5%

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Competitors Analysis of Other Non-Current Assets

CATX · AMEX
CompanyOther Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
486.00K
38.7%-12.1%-3.5% 
18.00K
-66.2%-31.0%N/A
2.48M
149.0%95.1%32.9%
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
2.47M
85.3%50.8%N/A
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
25.61M
427.0%50.7%N/A
9.95M
-15.7%-12.2%44.5%
HSDT logo
Solana Company
NASDAQ:HSDT
267.16M
1140.4%N/AN/A
Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Fair Value Envelope

CATX · AMEX

Our analysis suggests that CATX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.33, this represents a potential HIDDEN relative to our calculated worth for Perspective Therapeutics, Inc..

Intrinsic Value
Current Price: $3.33